Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Bioequivalence Study of JTE-052 Lotion vs Ointment in Pediatric Atopic Dermatitis
jRCT2031250221Phase 3Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of delgocitinib in atopic dermatitis (AD) (2 arms), sponsored by Shionogi & Co., Ltd. Primary endpoint: Percent change in modified Eczema Area and Severity Index (mEASI) score from baseline to end of treatment. Started Aug 2025; status: completed.
02
Drugs
delgocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2031250221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250221.